Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK” or the “Subsidiary”), will participate at the upcoming Mushroom Summit, taking place on June 19-20th, and Psychedelic Science, taking place on June 21-23rd in Denver Colorado.
Mushroom Summit
The Mushroom Summit 2023 will bring together industry veterans, entrepreneurs, investors, scientists and the curious to share knowledge, best practices and a common vision to support the strong, sustainable and responsible growth of this emerging sector.
Andrew Charrette, Director Regulatory Affairs, KGK Science Inc., will participate on the “Decomposing Regulatory Risk: How to Develop and Market Compliant and Impactful Myco Products” panel at 2:30pm MDT on June 20th.
Register to attend here.
Psychedelic Science
Psychedelic Science 2023 is the premier opportunity to reach a passionate audience over five days in Denver at the largest psychedelic community gathering in history.
Andrew Charrette will participate on several panels:
- Recreational vs Rx Market – The Future of Natural Psychedelics in the Kaleidoscope of Evolving Regulations (11:30 a.m. MDT on June 21st);
- Show Me the Data – Navigating Psychedelic Naysayers (10:15 a.m. MDT on June 22nd);
- Successful Protocol Designs for Psychedelic Clinical Trials – Use of Imaging, Biomarkers and Patient-Reported Outcomes (3:45 p.m. on June 22nd).
Najla Guthrie, CEO of KGK & Wellbeing will participate on two panels:
- Elephant in the Room? Safety and Abuse Liability in the Development of Psychedelic Drugs and Psychoactive Foods (3:45 p.m. MDT on June 21st);
- Show Me the Data – Navigating Psychedelic Naysayers (10:15 a.m. MDT on June 22nd).
Register to attend here.
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at ndolphin@wellbeingdigital.co.
ABOUT KGK SCIENCE
Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.
On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230619984334/en/